β-Blockers or β–Agonists? That’s the Question in the COPD Management

Copyright: © 2013 Ghanei M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Beta-blockers have long been known as agents posing bronchospasm in medical literature, and this has made physicians to have a reasonable fear in employing these agents for managing cardiovascular complications in the Chronic Obstructive Pulmonary Disease (COPD). On the other hand, cardiovascular comorbidities, alongside cancers, are the leading causes of mortality in mild to moderate COPD patients [1], and β-blockers have secured ther position as one of the bestdistinguished cardioprotective agents with the highest effectiveness and lowest rate of side-effects, in the current literature.